Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free TCRT Stock Alerts

Alaunos Therapeutics (TCRT) Competitors

Alaunos Therapeutics logo
$0.91 +0.02 (+2.65%)
As of 01:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

TCRT vs. BCLI, BLRX, PHIO, KALA, and ENLV

Should you buy Alaunos Therapeutics stock or one of its competitors? Alaunos Therapeutics's main competitors and comparable companies include Brainstorm Cell Therapeutics (BCLI), BioLineRx (BLRX), Phio Pharmaceuticals (PHIO), KALA BIO (KALA), and Enlivex Therapeutics (ENLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alaunos Therapeutics compare to Brainstorm Cell Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 1 articles in the media. Alaunos Therapeutics' average media sentiment score of 1.79 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Alaunos Therapeutics Very Positive
Brainstorm Cell Therapeutics Neutral

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -232.60% -158.99%
Brainstorm Cell Therapeutics N/A N/A -519.50%

Alaunos Therapeutics has a beta of -0.97, indicating that its stock price is 197% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Alaunos Therapeutics beats Brainstorm Cell Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Alaunos Therapeutics compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

BioLineRx has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -0.97, indicating that its share price is 197% less volatile than the broader market.

BioLineRx has higher revenue and earnings than Alaunos Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLineRx$1.18M9.58-$1.17M-$1.69N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, BioLineRx had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for BioLineRx and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.79 beat BioLineRx's score of 0.60 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
BioLineRx Positive
Alaunos Therapeutics Very Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Alaunos Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BioLineRx-502.08% -34.80% -18.27%
Alaunos Therapeutics N/A -232.60%-158.99%

Summary

BioLineRx beats Alaunos Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phio PharmaceuticalsN/AN/A-$8.70M-$1.29N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

Phio Pharmaceuticals' return on equity of -87.41% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Phio PharmaceuticalsN/A -87.41% -79.76%
Alaunos Therapeutics N/A -232.60%-158.99%

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -0.97, suggesting that its stock price is 197% less volatile than the broader market.

In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Phio Pharmaceuticals and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.79 beat Phio Pharmaceuticals' score of 1.26 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Phio Pharmaceuticals Positive
Alaunos Therapeutics Very Positive

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,265.85%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Phio Pharmaceuticals is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phio Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Phio Pharmaceuticals beats Alaunos Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

KALA BIO's return on equity of -222.35% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -222.35% -70.23%
Alaunos Therapeutics N/A -232.60%-158.99%

KALA BIO has a beta of -2.28, meaning that its stock price is 328% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -0.97, meaning that its stock price is 197% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, KALA BIO had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 4 mentions for KALA BIO and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.79 beat KALA BIO's score of 0.38 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
KALA BIO Neutral
Alaunos Therapeutics Very Positive

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$31.96N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

Summary

Alaunos Therapeutics beats KALA BIO on 6 of the 10 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Enlivex Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -0.97, meaning that its stock price is 197% less volatile than the broader market.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$1.24B-$8.25N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

Enlivex Therapeutics' return on equity of 248.08% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex TherapeuticsN/A 248.08% 206.39%
Alaunos Therapeutics N/A -232.60%-158.99%

Enlivex Therapeutics currently has a consensus target price of $247.50, indicating a potential upside of 57,191.67%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Enlivex Therapeutics had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.79 beat Enlivex Therapeutics' score of 0.94 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Enlivex Therapeutics Positive
Alaunos Therapeutics Very Positive

Summary

Enlivex Therapeutics beats Alaunos Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRT vs. The Competition

Export
MetricAlaunos TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.31M$3.89B$7.13B$13.01B
Dividend YieldN/A3.63%2.52%14.40%
P/E Ratio-0.4813.65273.3725.78
Price / SalesN/A1,295.97656.74105.59
Price / CashN/A120.9979.7552.18
Price / Book0.9815.7010.536.26
Net Income-$4.18M-$22.67M$3.49B$360.84M
7 Day Performance-19.38%-2.61%-2.03%-1.88%
1 Month Performance-45.12%-8.57%-5.22%-3.41%
1 Year Performance-63.27%23.88%10.28%2.64%

Alaunos Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
1.0044 of 5 stars		$0.91
+2.6%		N/A-63.2%$2.31MN/AN/A1
BCLI
Brainstorm Cell Therapeutics
N/A$0.95
+9.2%		N/A+34.3%$12.41MN/AN/A40
BLRX
BioLineRx
0.5954 of 5 stars		$2.52
-1.6%		N/A-37.8%$11.78M$1.18MN/A24
PHIO
Phio Pharmaceuticals
4.5565 of 5 stars		$1.02
flat		$14.00
+1,272.5%		-58.5%$11.62MN/AN/A6
KALA
KALA BIO
0.5798 of 5 stars		$0.56
flat		$75.00
+13,292.9%		-99.4%$11.59MN/AN/A6

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 10/1/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel